HX111 completes first patient dosing in Phase I clinical trial
February 5, 2026
Source: drugdu
27
On February 4, Hansit Aite (03378) announced that it has launched a Phase I clinical trial of its self-developed candidate drug HX111 for refractory lymphoma and solid tumors, and has recently successfully completed the enrollment and dosing of the first patient.
HX111 can bind to OX40 molecules on the surface of tumor cells with high affinity and high specificity. After entering tumor cells via endocytosis, it releases a powerful payload by lysosomal protease cleavage of the linker, thereby inducing tumor cell apoptosis.
The company's HX111 is the world's first publicly disclosed OX40-targeted ADC drug to enter the clinical stage. This field is still in the early exploration stage and is expected to fill the gap in the treatment of this type of tumor.
https://finance.eastmoney.com/a/202602043641684563.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Aligning with international standards! Aidea Pharma obtains Tanzania’s ML3 GMP certification February 5, 2026
- Shijiazhuang Pharmaceutical Group’s clopidogrel emulsion injection has received a drug registration certificate. February 5, 2026
- Human Coagulation Factor IX Drug Registration and Marketing Authorization Application Accepted February 5, 2026
- When the 31-valent pneumococcal vaccine begins Phase 3 clinical trials February 5, 2026
- Eli Lilly invests 24.3 billion yuan more in weight-loss drugs February 5, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
